Ptc Therapeutics (PTCT) Fundamental Analysis: Revenue, Earnings & Valuation

6.62 / 10

Outperform

Fundamentals rate Outperform with a 6.6/10 rating. High gross profit margin (97.3%) and low tax-to-profit ratio boost quality, while cash‑to‑market value and profit‑to‑market value are strong. Asset‑and revenue‑to‑market values lag, indicating modest valuation gaps.

Analysis Checks(10/10)

Revenue-MV

Value-1.37

Score3/3

Weight16.22%

1M Return9.51%

Inventory turnover ratio

Value0.91

Score2/3

Weight-0.60%

1M Return-0.56%

Gross profit margin (%)

Value97.28

Score2/3

Weight2.10%

1M Return1.67%

Profit-MV

Value1.68

Score3/3

Weight18.28%

1M Return9.40%

Income tax / Total profit (%)

Value2.01

Score2/3

Weight1.17%

1M Return0.98%

Current assets turnover ratio

Value0.95

Score3/3

Weight11.76%

1M Return7.57%

Fixed assets turnover ratio

Value29.75

Score2/3

Weight0.01%

1M Return0.01%

Cost of sales ratio (%)

Value2.72

Score2/3

Weight-3.82%

1M Return-3.62%

Asset-MV

Value-0.55

Score2/3

Weight22.77%

1M Return13.10%

Cash-MV

Value0.03

Score3/3

Weight32.12%

1M Return15.07%

Is PTCT undervalued or overvalued?

PTCT scores 6.62/10 on fundamentals and holds a Discounted valuation at present. Backed by its 0.00% ROE, 39.44% net margin, 8.05 P/E ratio, -26.77 P/B ratio, and 281.40% earnings growth, these metrics solidify its Outperform investment rating.